Last reviewed · How we verify
VSA012
At a glance
| Generic name | VSA012 |
|---|---|
| Sponsor | Visirna Therapeutics HK Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of of VSA012 in Subjects with Paroxysmal Nocturnal Hemoglobinuria(PNH)
- A Phase I Clinical Study of VSA012 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VSA012 CI brief — competitive landscape report
- VSA012 updates RSS · CI watch RSS
- Visirna Therapeutics HK Limited portfolio CI